CD8A-binding fibronectin type III domains

Patent metadata

Field	Value
Publication number	US-11932680-B2
Application number	US-202217689869-A
Country	US
Kind code	B2
Filing date	Mar 8, 2022
Priority date	Dec 14, 2016
Publication date	Mar 19, 2024
Grant date	Mar 19, 2024

Abstract

Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

First claim

What is claimed:

1. An isolated polynucleotide encoding a FN3 domain that specifically binds to a human CD8A protein comprising one of the amino acid sequences of SEQ ID NOs: 40-269.

2. A vector comprising the polynucleotide of claim 1 .

3. An isolated host cell comprising the vector of claim 2 .

4. A method of producing an FN3 domain that specifically binds to a human CD8A protein, comprising culturing the isolated host cell of claim 3 under conditions such that the FN3 domain is expressed, and purifying the FN3 domain.

Assignees

• Janssen Biotech Inc

Inventors

• Hawkins Rebecca
• Jacobs Steven
• Sepulveda Manuel

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/575

  for cancer · CPC title

• C07K14/78 Primary

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title

• A61K49/0002

  General or multifunctional contrast agents, e.g. chelated agents · CPC title

• A61K51/088

  conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10) · CPC title